For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...

Multi-channel models enhance cardiotoxicity testing, offering more accurate and human-relevant insights for safer drug ...

Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...

Bank of America Securities analyst Jason Zemansky has maintained their neutral stance on CYTK stock, giving a Hold rating on September 9.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...

Edgewise's lead drug, Sevasemten, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular ...

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price ...

Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high ...

AngioDynamics, Inc. announced the launch of the RECOVER AV trial of the company’s AlphaVac F18⁸⁵ multipurpose mecha ...

Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...